O
Ovid Therapeutics Inc. (OVID)
NCM – Real vaqt narxi. Valyuta: USD
2.55
+0.13 (5.37%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.55
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 7:37 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.55
+0.13 (5.37%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.55
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 7:37 PM EDT
Ovid Therapeutics Inc., biotexnologiya kompaniyasi, AQShda epilepsiya va tirishish bilan bog'liq nevrologik kasalliklar, shu jumladan miya kasalliklari uchun kichik molekulali dori vositalarini ishlab chiqish bilan shug'ullanadi. Kompaniya OV329, GABAA-AT inhibitorni ishlab chiqmoqda, u kattalar va chaqaloqlardagi dori-darmonga chidamli epilepsiyani davolash uchun 1-bosqich klinik sinovlarida; va OV4071, Parkinson kasalligi, Lewy tana demansiyasi va o'tkir shizofreniya bilan bog'liq psixozni davolash uchun 1-bosqich klinik sinovlarida bo'lgan birinchi inson og'zaki kaliy-xlorid kotransporter 2 to'g'ridan-to'g'ri faollashtiruvchisi. Kompaniya AstraZeneca AB, H. Lundbeck A/S, Shimoli-g'arbiy universitet va Graviton, shuningdek Marinus Pharmaceuticals, Inc. bilan litsenziya va hamkorlik shartnomalariga ega. Kompaniya 2014 yilda tashkil etilgan va shtab-kvartirasi Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder & Executive Chairman |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Dr. Zhong Zhong Ph.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-11 | 8-K | ovid-20260611.htm |
| 2026-06-03 | 8-K | ovid-20260602.htm |
| 2026-05-12 | 8-K | ovid-20260512.htm |
| 2026-05-12 | 10-Q | ovid-20260331.htm |
| 2026-04-27 | DEFA14A | ovid-20260427.htm |
| 2026-04-27 | DEF 14A | ovid-20260427.htm |
| 2026-04-27 | ARS | a2025form10kforannualreport.pdf |
| 2026-04-23 | CORRESP | filename1.htm |
| 2026-04-21 | S-3 | d108102ds3.htm |
| 2026-04-20 | 8-K | ovid-20260420.htm |
| Chief Scientific Officer |
| Mr. Charles Ross Carter | Senior VP of Finance & Financial Planning |
| Mr. Jeffrey A. Rona | Chief Business & Financial Officer and Corporate Secretary |
| Ms. Margaret Alexander | CEO, President & Director |
| Ms. Victoria Fort | Senior Vice President of Corporate Affairs & Corporate Strategy |